Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load, extensive local expertise on HCC has been accumulated. This article summarized local guidelines and real-life practice on HCC management in Hong Kong. For HCC surveillance, liver ultrasound and serum alpha-fetoprotein for periodic screening is recommended in viral hepatitis or cirrhotic patients, and this is adhered to in clinical practice. HCC diagnosis is not covered in local guidelines, yet our practice is in-line with regional guidelines, where diagnosis is usually achieved by cross-sectional imaging and without the need for histology. Our guidelines recommend using the Hong Kong Liver Cancer Staging for pre-treatment staging, yet we routinely use other widely-adopted systems such as the Barcelona Clinic Liver Cancer Staging and the Tumor-Node-Metastasis Staging as well. Our local guidelines have provided clear treatment algorithms for the whole range of HCC therapies, including resection, ablation, transplant, transarterial chemoembolization, transarterial radioembolization, stereotactic body radiation therapy, targeted therapy, and immunotherapy. Real-life treatment choices are largely in line with the guidelines, although treatment protocols are individualized, and availability of specific therapies can vary between centers. Overall, HCC guidelines in Hong Kong are tailored based on local expertise and our unique patient population. The guidelines are up-to-date and provide practical pathways to assist our routine practice. Regular updates of local guidelines are warranted to account for the rapidly evolving paradigm of HCC management.
Citations
Citations to this article as recorded by
Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen Gut.2026; 75(1): 119. CrossRef
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip Alimentary Pharmacology & Therapeutics.2026; 63(3): 383. CrossRef
A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma J. M. John Britto, T Beula Bell Irish Journal of Medical Science (1971 -).2026; 195(2): 1051. CrossRef
A deep learning radiopathomic signature predicts recurrence risk of hepatocellular carcinoma after hepatectomy Gongzheng Wang, Wei Chen, Zhuoshuai Liang, Feier Ding, Jin Cui, Zijian Shen, Fan Lin, Xiujuan Li, Ximing Wang, Xinya Zhao Communications Biology.2026;[Epub] CrossRef
Targeting the innate immune system in treating hepatitis B: prospects for functional cure Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Clinical and Molecular Hepatology.2026; 32(1): 184. CrossRef
Advancements in locoregional therapy for advanced hepatocellular carcinoma: Emerging perspectives on combined treatment strategies Qi Liu, Renjie Zhang, Weixi Shen European Journal of Surgical Oncology.2025; 51(2): 109502. CrossRef
Investigational RNA Interference Agents for Hepatitis B Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen BioDrugs.2025; 39(1): 21. CrossRef
Gold(I) complexes bearing EGFR-inhibiting ligands as anti-HCC agents through dual targeting of EGFR and TrxR Yawen Wang, Xiaoyan Ma, Xuejie Chen, Zhenfan Wen, Chunyang Bi, Zhongren Xu, Wukun Liu European Journal of Medicinal Chemistry.2025; 283: 117137. CrossRef
Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery Rex Wan-Hin Hui, Keith Wan-Hang Chiu, I-Cheng Lee, Chenlu Wang, Ho-Ming Cheng, Jianliang Lu, Xianhua Mao, Sarah Yu, Lok-Ka Lam, Lung-Yi Mak, Tan-To Cheung, Nam-Hung Chia, Chin-Cheung Cheung, Wai-Kuen Kan, Tiffany Cho-Lam Wong, Albert Chi-Yan Chan, Yi-Hsia Hepatology.2025; 82(2): 344. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients? Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Hepatology International.2025; 19(2): 304. CrossRef
Prospect of emerging treatments for hepatitis B virus functional cure Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2025; 31(Suppl): S165. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Hepatology International.2025; 19(4): 704. CrossRef
Comparative prognostic performance of staging systems for hepatocellular carcinoma: Evidence from a Vietnamese cohort study Tuong-Anh Mai-Phan, Trong-Kha Nguyen, Tri-Nhan Pham, Minh-Quang Tran, Kim-Long Le World Journal of Hepatology.2025;[Epub] CrossRef
The Prevailing Role of Diabetes Mellitus Among Cardiometabolic Risk Factors in Metabolic Dysfunction-associated Steatotic Liver Disease Prognostication Karen Cheuk-Ying Ho, Lung-Yi Mak Journal of Clinical and Experimental Hepatology.2025; 15(5): 103119. CrossRef
15-Year Trends in Hepatocellular Carcinoma: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry Songgyung Kim, Jina Park, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Ki-Hun Kim, Jonggi Choi Gut and Liver.2025; 19(5): 746. CrossRef
Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors Rex Wan-Hin Hui, Matthew Shing-Hin Chung, Lu Li, Xianhua Mao, Chi-Leung Chiang, Carlos King-Ho Wong, Ian Chi-Kei Wong, Ka-Shing Cheung, Man-Fung Yuen, Wai-Kay Seto, Lung-Yi Mak JHEP Reports.2025; 7(11): 101578. CrossRef
Development of a novel routine blood-based AI model for hepatocellular carcinoma screening—a territory-wide study K.-N. Kwok, K.-M. Chueng, S.J.-L. Lam, M. Seo, C.Y. Lau, P.Y.-M. Woo, H.-S. Lam, S.-M. Yip, S. Lam, O.-P. Chiu, W.W.Y. Sung, H.H.-W. Liu, K.K.-H. Bao, J.C.-H. Chow, S.K.-K. Ng, H.H.-Y. Yiu, D.C.C. Lam ESMO Gastrointestinal Oncology.2025; 10: 100241. CrossRef
Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts Jacqueline Schönherr, Philipp Seifert, Falk Gühne, Thomas Winkens, Falk Rauchfuß, Utz Settmacher, Martin Freesmeyer, Robert Drescher Cancers.2024; 16(1): 235. CrossRef
Hepatocellular carcinoma: Advances in systemic therapies Trevor Kwan-Hung Wu, Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen F1000Research.2024; 13: 104. CrossRef
ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B Ryan Hin-Man Leung, Rex Wan-Hin Hui, Lung-Yi Mak, Xianhua Mao, Kevin Sze-Hang Liu, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Man-Fung Yuen Journal of Hepatology.2024; 81(2): 218. CrossRef
Hepatocellular carcinoma: Advances in systemic therapies Trevor Kwan-Hung Wu, Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen F1000Research.2024; 13: 104. CrossRef
Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions Sergei Noskov, Anna Arefeva, Kseniia Radaeva, Igor Makarenko, Maria Gefen, Roman Drai Clinical Pharmacology in Drug Development.2024; 13(10): 1123. CrossRef
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen, James Fung Expert Review of Gastroenterology & Hepatology.2023; 17(5): 443. CrossRef
The prime time for management of hepatocellular carcinoma in Hong Kong Landon L. Chan, Stephen L. Chan Clinical and Molecular Hepatology.2023; 29(2): 345. CrossRef
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(2): 252. CrossRef
World Hepatitis Day 2023: Are we close to the target? Rex Wan-Hin Hui, James Fung Indian Journal of Medical Research.2023; 158(1): 1. CrossRef
Global trends of targeted therapy for hepatocellular carcinoma: A bibliometric and visualized study from 2008 to 2022 Xuan-Ang Yang, Rong Jin, Lei-Ming Zhang, Dong-Jian Ying Medicine.2023; 102(34): e34932. CrossRef
First
Prev
